Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female greater than 18 years of age;~* Previously met the preliminary criteria of the American Rheumatism Association (ARA) for the classification of the acute arthritis of primary gout;~* At least 2 gout flares in the year prior to the screening visit.~Exclusion Criteria:~* Acute gout flare within 2 weeks of the screening visit and during screening;~* Persistent chronic or active infections;~* History of an allergic reaction to allopurinol;~* History or presence of cancer within 5 years of the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 16.
- Rilonacept 160 mg (Type: EXPERIMENTAL): Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 16.

Based on this trial design, predict the completion outcome and termination type (if applicable).